[Therapies for newly-onset diabetic patients].
Kawamori
Ryuzo
R
Department of Medicine, Juntendo University School of Medicine.
D020909:Acarbose / Q000494:pharmacology / Q000627:therapeutic use; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D004035:Diet Therapy; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005081:Exercise Therapy; D005947:Glucose / Q000378:metabolism; D018149:Glucose Intolerance / Q000150:complications; D006003:Glycogen / Q000378:metabolism; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use
D003510:Cyclohexanes; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D000077715:Nateglinide; D010649:Phenylalanine; C057619:glimepiride; D006003:Glycogen; D008687:Metformin; D005947:Glucose; D020909:Acarbose